文献速递肝病

逝世后肝移植后输注间充质基质细胞:一项I-II期、开放标签、临床研究

Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.
PubMed 文献 · J Hepatol · 2017-03-09

这项前瞻性、对照性I期研究评估了肝移植受者单次输注间充质基质细胞(MSC)的可行性、安全性和耐受性。10例受者术后第3±2天接受1.5-3×10^6/kg第三方无关MSC,与10例对照比较;未检测到输注毒性,但未能促进免疫耐受,免疫抑制撤减未成功。

要点

  • 10例肝移植受者术后第3±2天输注1.5-3×10^6/kg第三方无关MSC,未检测到生命参数变化或细胞因子释放综合征。
  • MSC输注后无器官功能损害(包括移植肝功能),未检测到机会性感染或新发癌症发生率增加。
  • 两组总体排斥率或移植物存活无差异,MSC受者免疫抑制撤减未成功。

核心结论

  • 肝移植术后第3天输注MSC未检测到副作用,但该输注未促进免疫耐受。

研究设计与样本

  • 前瞻性、对照性I期研究,纳入10例接受标准免疫抑制的肝移植受者,术后第3±2天输注1.5-3×10^6/kg第三方无关MSC,并与10例肝移植受者对照组前瞻性比较。

主要发现

  • MSC输注期间及之后未检测到生命参数变化或细胞因子释放综合征。
  • MSC输注后无患者出现器官功能损害(包括移植肝功能)。
  • 未检测到机会性感染或新发癌症发生率增加。
  • 两组总体排斥率或移植物存活无差异。
  • 第6个月活检在Banff标准排斥评估、纤维化评分或免疫组化(包括调节性T细胞)方面组间无差异,外周血淋巴细胞分型无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mesenchymal stromal cell (MSC) infusion could be a means to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase I study was to evaluate the feasibility, safety and tolerability of a single infusion of MSCs in liver transplant recipients. METHODS: Ten liver transplant recipients under standard immunosuppression received 1.5-3×106/kg third-party unrelated MSCs on postoperative day 3±2, and were prospectively compared to a control group of ten liver transplant recipients. As primary endpoints, MSC infusion toxicity was evaluated, and infectious and cancerous complications were prospectively recorded until month 12 in both groups. As secondary endpoints, rejection rate, month-6 graft biopsies, and peripheral blood lymphocyte phenotyping were compared. Progressive immunosuppression weaning was attempted from month 6 to 12 in MSC recipients. RESULTS: No variation in vital parameters or cytokine release syndrome could be detected during and after MSC infusion. No patient developed impairment of organ functions (including liver graft function) following MSC infusion. No increased rate of opportunistic infection or de novo cancer was detected. As secondary endpoints, there was no difference in overall rates of rejection or graft survival. Month-6 biopsies did not demonstrate a difference between groups in the evaluation of rejection according to the Banff criteria, in the fibrosis score or in immunohistochemistry (including Tregs). No difference in peripheral blood lymphocyte typing could be detected. The immunosuppression weaning in MSC recipients was not successful. CONCLUSIONS: No side effect of MSC infusion at day 3 after liver transplant could be detected, but this infusion did not promote tolerance. This study opens the way for further MSC or Treg-based trials in liver transplant recipients. LAY SUMMARY: Therapy with mesenchymal stromal cells (MSCs) has been proposed as a means to improve results of solid organ transplantation. One of the potential MSC role could be to induce tolerance after liver transplantation, i.e. allowing the cessation of several medications with severe side effects. This study is the first-in-man use of MSC therapy in ten liver transplant recipients. This study did not show toxicity after a single MSC infusion but it was not sufficient to allow withdrawal of immunosuppression. CLINICAL TRIAL REGISTRATION NUMBER: Eudract: # 2011-001822-81, ClinicalTrials.gov: # NCT 01429038.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Detry O, Vandermeulen M, Delbouille MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. J Hepatol. 2017. PMID: 28284916. doi:10.1016/j.jhep.2017.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。